Longitudinal study of immunity to SARS‐CoV2 in ocrelizumab‐treated MS patients up to 2 years after COVID‐19 vaccination
Objectives (1) To plot the trajectory of humoral and cellular immune responses to the primary
(two‐dose) COVID‐19 mRNA series and the third/booster dose in B‐cell‐depleted multiple …
(two‐dose) COVID‐19 mRNA series and the third/booster dose in B‐cell‐depleted multiple …
COVID-19 outcomes in patients with multiple sclerosis: understanding changes from 2020 to 2022
L Jeantin, E Januel, P Labauge… - Multiple Sclerosis …, 2024 - journals.sagepub.com
Background: Epidemiologic studies on coronavirus disease 2019 (COVID-19) in patients
with multiple sclerosis (pwMS) have focused on the first waves of the pandemic until early …
with multiple sclerosis (pwMS) have focused on the first waves of the pandemic until early …